-
Medical journals
- Career
News
Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
7. 9. 2021 Source: Chronic Heart Failure and LipidologyIvabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the synergistic effect of these modern medications.
Variability of COPD Symptoms During the Day and Impact on Patients' Morning Routine – Survey Results
Chronic obstructive pulmonary disease (COPD) is viewed, unlike bronchial asthma, as a condition with a more chronic course and less variability of symptoms throughout the day. The study presented…7. 9. 2021 Source: proLékaře.cz
Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage
The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium…2. 9. 2021 Source: Asthma under control
New Strategies in the Treatment of Schizophrenia
Schizophrenia was primarily associated with dopamine dysfunction. Previous and current treatments have mainly targeted the mesolimbic dopamine pathway in the CNS and D2 receptors. However, the cited…30. 8. 2021 Source: Schizophrenia and Antipsychotics
Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides…27. 8. 2021 Source: Anticoagulant Treatment
Is the combination of tiotropium/olodaterol proven more effective in reducing the risk of clinically significant worsening of COPD compared to monotherapy?
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), the use of a composite parameter that includes lung function, the occurrence of exacerbations, and quality of life offers a…26. 8. 2021 Source: proLékaře.cz
Impact of Chronic Urticaria on Patients' Quality of Life and Society
An international team of dermatologists has mapped out the impact of chronic urticaria on various aspects of patients' lives and the economic burden this long-term disease, without available causal…25. 8. 2021 Source: Allergic Reactions
Perioperative substitution therapy in patients with vWD must be tailored
Even in cases of von Willebrand disease (vWD), available data supports the need for individualized approaches in ensuring surgical procedures to prevent FVIII accumulation and high factor consumption.25. 8. 2021 Source: Von Willebrand Disease
Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease
A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors…25. 8. 2021 Source: Von Willebrand Disease
The Position of Lurasidone in Schizophrenia Therapy − Current Conclusions and Consensus of the Expert Panel
Lurasidone is an antipsychotic belonging to the group of serotonin and dopamine antagonists (SDA) indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. The…24. 8. 2021 Source: Modern Treatment of Schizophrenia
Recommendations for Nutrition of Patients at Risk of or with Pressure Ulcers
Nutrition plays a crucial role in the prevention and treatment of pressure ulcers. In 2019, international recommendations for the nutrition of individuals at risk of or already with pressure ulcers…23. 8. 2021 Source: Wound Healing
Classification and Management of Chronic Wounds
Chronic wounds are common comorbidities that increase the morbidity and mortality of patients. Common types of chronic wounds on the lower extremities include arterial, venous, and diabetic ulcers,…23. 8. 2021 Source: Wound Healing
Efficacy of Panitumumab in the Treatment of Refractory mCRC
A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher overall response rate compared to controls in patients with refractory metastatic colorectal cancer (mCRC).20. 8. 2021 Source: Colorectal Cancer
Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has been increasing in recent years. Currently, diabetics make up approximately 8−10% of the population. The…20. 8. 2021 Source: Heart Failure
Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a…20. 8. 2021 Source: Heart Failure
Popular this week- Colorectal cancer and comorbidities – implications for surgical practice
- Telemedicine video consultations in the Czech Republic and their practical implementation in outpatient practice
- Obesity during pregnancy – health risks and prevention options
- Periodontitis and type 2 diabetes
- Eligibility to hold a driving license for seniors and current legislation
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career